Publication | Closed Access

Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell lung cancer after failure of first-line chemotherapy: GFPC 10.02 study

MedicineMetronomic TherapyDocetaxel Versus DocetaxelClinical TrialsSequential ErlotinibBronchial NeoplasmPharmacotherapyCancer TreatmentGfpc 10.02OncologyRadiation OncologyLung CancerMolecular OncologyRadiologyHealth Sciences